[CAS NO. 2490672-92-7] TDO-IN-1
PRODUCTS SPECIFICATIONS [2490672-92-7]
DESCRIPTION [2490672-92-7]
Overview
| MDL | - |
|---|---|
| Molecular Weight | 350.30 |
| Molecular Formula | C16H13F3N4O2 |
| SMILES | FC(C1=CC2=C(C(NCC3=CC=C(C)C=C3[N+]([O-])=O)=C1)C=NN2)(F)F |
Summary
IC50 & Target
IC50: 0.62 μM (tryptophan 2,3-dioxygenase, TDO) [1]
In Vitro
TDO-IN-1 (HT-28) (0-100 μM; 24 h) shows significant tumoricidal effect on different tumor lines, with IC
50
s of 0.54 μM (HepG2), 5.08 μM (Hepa1-6), 1.34 μM (H22), 37.39 μM (B16), 3.43 μM (MOLM-13), and 7.25 μM (Jurkat), respectively
[1]
.
TDO-IN-1 (0-100 μM; 24 h) exhibits few cytotoxic activity against normal cells (HEK 293 cells) below 10 μM
[1]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
TDO-IN-1 (HT-28) (25 mg/kg; p.o.; once daily; 9 d) improve the effect of tumor immunotherapy of CT26 tumor expressing TDO, substantially inhibits the proliferation of CT26 tumors in mice
[1]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
| Animal Model: | CT-26 allograft BALB/c mice (6-8 weeks old, female) [1] |
| Dosage: | 12.5, 25, and 50 mg/kg |
| Administration: | Oral gavage; once daily; 9 days |
| Result: |
Resulted significant reduction in tumor weight and volume in mice, with the tumor volume inhibiton rate of 76.93%.
Reduced the expression of Foxp3 and enhance the expression of CD8 and TNF-α in tumor tissue to increase the immune response of tumor-bearing mice. |
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.